{"id":3789,"date":"2024-11-15T10:06:10","date_gmt":"2024-11-15T07:06:10","guid":{"rendered":"https:\/\/pharmaworlddergi.com\/?p=3789"},"modified":"2024-11-15T11:28:10","modified_gmt":"2024-11-15T08:28:10","slug":"amacimiz-yenilikci-urunlerimizi-hastalar-icin-erisilebilir-hale-getirmek","status":"publish","type":"post","link":"https:\/\/pharmaworlddergi.com\/?p=3789","title":{"rendered":"Amac\u0131m\u0131z, Yenilik\u00e7i \u00dcr\u00fcnlerimizi Hastalar i\u00e7in Eri\u015filebilir Hale Getirmek"},"content":{"rendered":"\n

MSD T\u00fcrkiye B\u00f6lgesi (T\u00fcrkiye, Ukrayna ve CIS \u00dclkeleri) K\u0131demli Ruhsatland\u0131rma Direkt\u00f6r\u00fc<\/strong> <\/strong>Ebru \u00c7ak\u0131c\u0131, MSD\u2019nin ruhsatland\u0131rma departman\u0131 ve \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda bilgi vererek, \u00fclkemizdeki ila\u00e7 ruhsatland\u0131rma s\u00fcre\u00e7lerine ili\u015fkin g\u00f6r\u00fc\u015flerini payla\u015ft\u0131.<\/strong> <\/strong><\/strong><\/p>\n\n\n\n

Sizi ve MSD Ruhsatland\u0131rma Ekibi\u2019ni tan\u0131yabilir miyiz?<\/strong><\/p>\n\n\n

\n
\"\"<\/figure><\/div>\n\n\n

ODT\u00dc Kimya B\u00f6l\u00fcm\u00fc mezunuyum. Ayn\u0131 \u00fcniversitede biyoteknoloji y\u00fcksek lisans\u0131m\u0131 tamamlad\u0131m. Yakla\u015f\u0131k 24 y\u0131ld\u0131r ila\u00e7 sekt\u00f6r\u00fcnde farkl\u0131 pozisyonlarda \u00e7al\u0131\u015f\u0131yorum. 2014\u2019te MSD Ruhsatland\u0131rma Ekibi\u2019ne kalite g\u00fcvence m\u00fcd\u00fcr\u00fc olarak kat\u0131ld\u0131m ve 2018\u2019den beri ruhsatland\u0131rma direkt\u00f6r\u00fc olarak g\u00f6rev yap\u0131yorum. <\/p>\n\n\n\n

MSD Ruhsatland\u0131rma Departman\u0131\u2019nda eczac\u0131 ve kimyager a\u011f\u0131rl\u0131kl\u0131 farkl\u0131 akademik ge\u00e7mi\u015flere sahip 10 ki\u015filik bir ekibiz. Ekimibizde 2 ruhsatland\u0131rma m\u00fcd\u00fcr\u00fc, 4 k\u0131demli ruhsatland\u0131rma uzman\u0131, 2 ruhsatland\u0131rma uzman\u0131, 1 b\u00f6l\u00fcm asistan\u0131 bulunuyor. Ayr\u0131ca, ihtiya\u00e7lara ba\u011fl\u0131 olarak kontratl\u0131 \u00e7al\u0131\u015fanlar ve stajyerler de ekibe kat\u0131labiliyor.<\/p>\n\n\n\n

Onkoloji ve a\u015f\u0131 gibi alanlar da dahil olmak \u00fczere farkl\u0131 terap\u00f6tik alanlarda 50\u2019den fazla ruhsatl\u0131 \u00fcr\u00fcn\u00fcm\u00fcz bulunuyor.<\/p>\n\n\n\n

Ruhsatland\u0131rma biriminin \u015firket i\u00e7indeki ve d\u0131\u015f\u0131ndaki payda\u015flar\u0131 kimler, payda\u015flar\u0131n\u0131zla nas\u0131l i\u015f birlikleri y\u00fcr\u00fct\u00fcyorsunuz?<\/strong><\/p>\n\n\n\n

Ana payda\u015f\u0131m\u0131z Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ve T\u00fcrk \u0130la\u00e7 ve T\u0131bbi Cihaz Kurumu (T\u0130TCK). \u015eirket i\u00e7inde ise hastalar\u0131n ilaca kesintisiz eri\u015fimini sa\u011flamak i\u00e7in farkl\u0131 \u00e7evik tak\u0131mlarda yer al\u0131yoruz. Global bir firma olman\u0131n getirdi\u011fi avantajlardan da yararlan\u0131yoruz. \u015eirketimizin i\u00e7 yap\u0131lanmas\u0131nda EEMEA (Do\u011fu Avrupa, Orta Do\u011fu ve Afrika) b\u00f6lgesinde yer al\u0131yoruz.\u00a0 B\u00f6lgesel ve global g\u00f6revler ile yeni bak\u0131\u015f a\u00e7\u0131lar\u0131 kazan\u0131yoruz. Yaln\u0131zca \u00fclke gereklilikleri de\u011fil, d\u00fczenleyici kurumlar\u0131 takip ederek, T\u0130TCK’n\u0131n y\u00f6nergelerine uyumlu \u00e7al\u0131\u015f\u0131yoruz. Ayr\u0131ca, Ara\u015ft\u0131rmac\u0131 \u0130la\u00e7 Firmalar\u0131 Derne\u011fi (AIFD) \u00fcyesi olarak farkl\u0131 platformlarda MSD\u2019yi temsil ediyoruz.<\/p>\n\n\n\n

Ruhsatland\u0131rma s\u00fcrecinde \u00fclkemizde ya\u015fanan en \u00f6nemli sorunlar sizce neler? S\u00fcreci iyile\u015ftirebilme ad\u0131na Sa\u011fl\u0131k Bakanl\u0131\u011f\u0131 ve T\u0130TCK\u2019dan ne gibi beklentileriniz var?<\/strong><\/p>\n\n\n\n

MSD olarak \u2018ya\u015fam i\u00e7in ke\u015ffediyoruz\u2019 diyerek yenilik\u00e7i ila\u00e7lar, a\u015f\u0131lar ve biyolojik \u00fcr\u00fcnler geli\u015ftiriyoruz. Ruhsatland\u0131rmada \u00f6ncelikli amac\u0131m\u0131z yenilik\u00e7i \u00fcr\u00fcnlerimizi hastalar i\u00e7in eri\u015filebilir hale getirmek. Bu hedefle T\u0130TCK\u2019n\u0131n ilgili birimleriyle yak\u0131ndan \u00e7al\u0131\u015f\u0131yoruz.<\/p>\n\n\n\n

Son y\u0131llarda T\u0130TCK, uluslararas\u0131 alandaki otoritesini sa\u011flamla\u015ft\u0131rmak i\u00e7in b\u00fcy\u00fck ad\u0131mlar att\u0131. Uluslararas\u0131 \u00fcyelikler, \u00fclkemizin ila\u00e7 sekt\u00f6r\u00fcn\u00fcn ilerlemesine katk\u0131da bulundu. Ayr\u0131ca 2023\u2019te D\u00fcnya Sa\u011fl\u0131k \u00d6rg\u00fct\u00fc (DS\u00d6) taraf\u0131ndan hem ila\u00e7 hem de a\u015f\u0131da 3. seviye olgunluk d\u00fczeyine eri\u015fen Ulusal D\u00fczenleyici Otorite olarak tan\u0131nd\u0131.<\/p>\n\n\n\n

Yenilik\u00e7i ila\u00e7lar\u0131n d\u00fcnyadaki ilk ruhsat onay tarihi ile \u00fclkemizdeki onay tarihi aras\u0131ndaki fark\u0131n k\u0131salt\u0131lmas\u0131 ve s\u00fcre\u00e7lerin mevzuat\u0131n imk\u00e2n verdi\u011fi \u00f6l\u00e7\u00fcde h\u0131zland\u0131r\u0131lmas\u0131n\u0131n daha fazla yenilik\u00e7i ilac\u0131n \u00fclkemize gelmesini sa\u011flayaca\u011f\u0131n\u0131 d\u00fc\u015f\u00fcn\u00fcyoruz. <\/p>\n\n\n\n

Ruhsatland\u0131rma alan\u0131nda \u00e7al\u0131\u015fmak i\u00e7in ne gibi yetkinlikler gerekiyor? Ekibinize dahil olacak \u00e7al\u0131\u015fma arkada\u015flar\u0131n\u0131z \u00f6ncelikle hangi \u00f6zelliklere sahip olmal\u0131lar?<\/strong><\/p>\n\n\n\n

MSD\u2019nin kurum k\u00fclt\u00fcr\u00fc \u00e7e\u015fitlilik, e\u015fitlik, kapsay\u0131c\u0131l\u0131k ve geli\u015fime dayan\u0131r. Ekibimizde her birey kendi alan\u0131nda liderdir ve ekibe farkl\u0131 \u00f6zellikleriyle katk\u0131da bulunur. Ruhsatland\u0131rma s\u00fcre\u00e7leri akademik bilgi, dikkat, \u00f6zen ve isteklilik gerektirir. Ekibimize kat\u0131lacak ki\u015filer hem ki\u015fisel hem i\u015f anlam\u0131nda geli\u015fime a\u00e7\u0131k, de\u011fi\u015fimleri y\u00f6netebilen, gerekti\u011finde liderlik yapabilen bireyler olmal\u0131d\u0131r.    <\/p>\n","protected":false},"excerpt":{"rendered":"

MSD T\u00fcrkiye B\u00f6lgesi (T\u00fcrkiye, Ukrayna ve CIS \u00dclkeleri) K\u0131demli Ruhsatland\u0131rma Direkt\u00f6r\u00fc\u00a0Ebru \u00c7ak\u0131c\u0131, MSD\u2019nin ruhsatland\u0131rma departman\u0131 ve \u00e7al\u0131\u015fmalar\u0131 hakk\u0131nda bilgi vererek, \u00fclkemizdeki ila\u00e7 ruhsatland\u0131rma s\u00fcre\u00e7lerine ili\u015fkin g\u00f6r\u00fc\u015flerini payla\u015ft\u0131. <\/p>\n","protected":false},"author":1,"featured_media":3791,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[48,2],"tags":[],"_links":{"self":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3789"}],"collection":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3789"}],"version-history":[{"count":6,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3789\/revisions"}],"predecessor-version":[{"id":3797,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/posts\/3789\/revisions\/3797"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=\/wp\/v2\/media\/3791"}],"wp:attachment":[{"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3789"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3789"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/pharmaworlddergi.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3789"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}